The Antibody Series (TAS) conference 2026, organized by FairJourney Biologics, will once more count with top industry and academic experts to share innovative ideas in antibody discovery and development. Curated by Chairwoman Dr. Laura Walker and Co-Chair Dr. John Desjarlais, 2026 event will be held in the amazing city of Évora in Portugal.
In the meantime, access The Antibody Series 2025’ on-demand lectures through our website, free of charge.
You can learn more about 2025’ agenda here.
| Speaker | Lecture Title |
| Peter Senter – Keynote | The Past, Present, and Future of Antibody Drug Conjugates |
| Greg Thurber | Opportunities for Protein Engineering to Improve the Efficacy of Antibody Drug Conjugates |
| Peter Tessier | Antibody optimization using machine learning and atomistic design |
| Ariel Tennenhouse | One-shot optimization of antibody affinity and developability through computational design |
| Richar McCormick | Go Big or Go Home: The Allure of Broad Patent Claims Directed to Antibody Functionality, and the Constraints of U.S. Patent Law |
| Annemiek van Spriel – Keynote | The biology and therapeutic potential of Tetraspanin Proteins |
| Pamela Holland | Remixing the immune synapse for the development of novel PD-1 targeting strategies |
| Diane Hollenbaugh | Conditional Protein Therapeutics using Dual-Binding Antibodies |
| Madelon Maurice | To be or not bE3? Targeted membrane protein degradation using heterobispecific antibodies (SureTACs) |
| Leo James | Trim-Away: TRIM21-based modalities for intracellular targeted protein degradation |
| Philip Brouwer
|
Structure-Driven Innovation: Discovery and Engineering Through CryoEM at FairJourney |
| Anna Huhn | A novel particle-based model captures the stochastic and spatial process of bivalent binding and predicts antibody function |
| Jan Terje Andersen | Antibody designs and effector function engineering for tailored outcome |
| Marina Bacac | From engagement to remodeling: How TCEs shape the tumor microenvironment and response |
| Katherine Harris | Co-stimulatory bispecific antibody strategies for treating solid tumors |
| Kevin Parker | Single-cell atlasing enables precision target selection for cell-specific antibody therapeutics |
